argenex SE $ARGX Position Decreased by Artisan Partners Limited Partnership

Artisan Partners Limited Partnership lessened its holdings in shares of argenex SE (NASDAQ:ARGX) by 19.6% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 1,756,942 shares of the company’s stock after selling 429,568 shares during the quarter. argenex makes up 2.2% of Artisan Partners Limited Partnership’s portfolio, making the stock its 8th largest holding. Artisan Partners Limited Partnership’s holdings in argenex were worth $1,477,501,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also modified their holdings of the business. &PARTNERS boosted its stake in shares of argenex by 30.3% during the 4th quarter. &PARTNERS now owns 1,897 shares of the company’s stock worth $1,595,000 after acquiring an additional 441 shares during the last quarter. Blair William & Co. IL boosted its stake in shares of argenex by 1,005.3% during the 4th quarter. Blair William & Co. IL now owns 26,340 shares of the company’s stock worth $22,151,000 after acquiring an additional 23,957 shares during the last quarter. Persistent Asset Partners Ltd purchased a new position in shares of argenex during the 4th quarter worth $474,000. USS Investment Management Ltd boosted its stake in shares of argenex by 4.8% during the 4th quarter. USS Investment Management Ltd now owns 11,997 shares of the company’s stock worth $10,092,000 after acquiring an additional 547 shares during the last quarter. Finally, Vanguard Personalized Indexing Management LLC boosted its stake in shares of argenex by 3.8% during the 4th quarter. Vanguard Personalized Indexing Management LLC now owns 3,472 shares of the company’s stock worth $2,920,000 after acquiring an additional 128 shares during the last quarter. Hedge funds and other institutional investors own 60.32% of the company’s stock.

argenex Stock Performance

ARGX opened at $878.49 on Wednesday. argenex SE has a fifty-two week low of $510.05 and a fifty-two week high of $934.62. The firm’s fifty day moving average is $817.48 and its 200 day moving average is $810.99. The stock has a market cap of $54.63 billion, a price-to-earnings ratio of 39.11, a price-to-earnings-growth ratio of 1.35 and a beta of 0.47.

argenex (NASDAQ:ARGX) last released its earnings results on Tuesday, March 31st. The company reported $5.52 earnings per share for the quarter. argenex had a net margin of 31.31% and a return on equity of 44.37%. The company had revenue of $1.31 billion for the quarter. On average, equities research analysts predict that argenex SE will post 26.19 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several research analysts have recently weighed in on ARGX shares. Guggenheim lifted their price target on shares of argenex from $1,120.00 to $1,135.00 and gave the stock a “buy” rating in a research note on Friday, May 8th. Citizens Jmp lifted their price target on shares of argenex from $925.00 to $944.00 and gave the stock a “market outperform” rating in a research note on Friday, February 27th. Oppenheimer dropped their price target on shares of argenex from $1,060.00 to $1,014.00 and set an “outperform” rating on the stock in a research note on Thursday, April 2nd. Wall Street Zen cut shares of argenex from a “buy” rating to a “hold” rating in a research note on Sunday, March 8th. Finally, Deutsche Bank Aktiengesellschaft upgraded shares of argenex from a “hold” rating to a “buy” rating in a research note on Tuesday, March 10th. Two equities research analysts have rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and four have issued a Hold rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $1,019.50.

About argenex

argenx (NASDAQ: ARGX) is a biotechnology company focused on the discovery, development and commercialization of antibody-based therapeutics for severe autoimmune and neuromuscular diseases. The company uses its proprietary SIMPLE Antibody platform to generate differentiated antibodies and engineered Fc regions, and it pursues mechanisms that modulate the neonatal Fc receptor (FcRn) to reduce pathogenic IgG levels. Argenx’s research and development activities span target identification, preclinical development and late-stage clinical programs aimed at addressing unmet needs in immunology.

The company’s lead product, efgartigimod (marketed as Vyvgart), is an FcRn antagonist developed to reduce circulating IgG antibodies and treat IgG-mediated disorders.